Travere Therapeutics (TVTX) Inventory (2014 - 2026)

Travere Therapeutics has reported Inventory for 13 years, with the latest figure at $6.4 million in Q1 2026.

• For the quarter ending Q1 2026, Inventory rose 61.65% year-over-year to $6.4 million; the trailing twelve-month figure through Mar 2026 stood at $6.4 million (up 61.65% YoY), and the FY2025 full-year result was $5.9 million, down 5.24% from the prior year.
• Inventory for Q1 2026 stood at $6.4 million, up from $5.9 million in the prior quarter.
• The five-year high for Inventory was $20.8 million in Q3 2023, with the low at $3.9 million in Q1 2025.
• Historically, Inventory has averaged $7.7 million across 5 years, with a median of $6.4 million in 2024.
• Annual changes were most pronounced in 2023 — Inventory jumped 184.68% — and 2024, when it slumped 69.4%.
• Travere Therapeutics' Inventory stood at $4.5 million in 2022, then jumped by 108.05% to $9.4 million in 2023, then tumbled by 34.11% to $6.2 million in 2024, then decreased by 5.24% to $5.9 million in 2025, then grew by 8.19% to $6.4 million in 2026.
• The last three Inventory figures came in at $6.4 million (Q1 2026), $5.9 million (Q4 2025), and $5.5 million (Q3 2025), per Business Quant data.